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ABSTRACT
The ultimate step common to almost all DNA repair
pathways is the ligation of the nicked intermediate
to form contiguous double-stranded DNA. In the
mammalian nucleotide and base excision repair
pathways, the ligation step is carried out by ligase
III-a. For efficient ligation, ligase III-a is constitutive-
ly bound to the scaffolding protein XRCC1 through
interactions between the C-terminal BRCT domains
of each protein. Although structural data for the in-
dividual domains has been available, no structure of
the complex has been determined and several alter-
native proposals for this interaction have been
advanced. Interpretation of the models is com-
plicated by the formation of homodimers that,
depending on the model, may either contribute to,
or compete with heterodimer formation. We report
here the structures of both homodimer complexes
as well as the heterodimer complex. Structural char-
acterization of the heterodimer formed from a
longer XRCC1 BRCT domain construct, including
residues comprising the interdomain linker region,
revealed an expanded heterodimer interface with
the ligase III-a BRCT domain. This enhanced
linker-mediated binding interface plays a significant
role in the determination of heterodimer/homodimer
selectivity. These data provide fundamental insights
into the structural basis of BRCT-mediated dimer-
ization, and resolve questions related to the organ-
ization of this important repair complex.
INTRODUCTION
The repair of damaged DNA requires the coordinated
action of multiple enzymes that interpret the damage,
excise the damaged components and re-synthesize the
DNA. X-ray cross complementing group 1 protein
(XRCC1) is a scaffold protein that plays a central role
in the organization of the base excision repair (BER)
and single-strand break (SSB) repair pathways by inter-
acting with and mediating interactions between the repair
proteins (1). Of the multiple binding partners that have
been identiﬁed (2–5), only one, DNA ligase III-a (L3a),
forms a constitutive XRCC1 complex (6). Efﬁcient DNA
nick ligation involves the participation of the XRCC1/L3a
complex that is mediated through the interaction of the
C-terminal BRCT domains of both proteins (7). This
interaction is required to maintain normal levels of
DNA ligase activity and DNA ligation is defective in the
absence of an XRCC1/L3a complex (6). In addition to the
more extensively studied roles of the XRCC1/L3a in
the SSB and BER pathways, recent studies indicate that
the XRCC1/L3a complex is also utilized for the ﬁnal
ligation step in the nucleotide excision repair (NER)
pathway in both dividing and non-dividing cells (8).
There is also evidence that the XRCC1/L3a complex par-
ticipates as a backup alternative in the non-homologous
end-joining pathway (9).
Although structural data has been available for the
C-terminal L3a BRCT (L3BRCT) and XRCC1 BRCT
(X1BRCTb) domains (10,11), the nature of the complex
that mediates the interaction of X1BRCTb and L3BRCT
has been unclear, and alternative structural proposals
involving different interfaces and stoichiometries have
been advanced (7,12,13). Dulic et al. (13) modeled the
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with X1BRCTb and further proposed a heterodimeric
X1BRCTb/L3BRCT structure analogous to the
X1BRCTb homodimer observed in the crystal. In
general, it is unclear why the repair proteins would
utilize a common interface allowing both homo- and
heterodimer formation, resulting in competitive dimeriza-
tion interactions. Alternatively, Beernink et al. (12)
proposed that since both X1BRCTb and L3BRCT form
stable homodimers, the biologically active unit involves
a BRCT tetramer formed by the association of the
two BRCT homodimers. Based on these studies, they
determined that the association rate of the heterodimer
was too fast to account for displacement of the homo-
dimers (12). According to this model, the biologically
active unit involves two copies of XRCC1 and L3a
forming the biochemically observed tetrameric quaternary
complex. Alternatively, Taylor et al. (7) have identiﬁed a
different X1BRCTb/L3BRCT dimerization interface,
centered around the a2–a3 loop residues 573–592 in
X1BRCTb. These alternative models have important
implications for understanding the function of the
XRCC1/L3a repair complex and for the interpretation
of XRCC1 nucleotide polymorphism data that is
becoming available (14,15).
To resolve competing models and to further understand
the basis of this BRCT heterodimerization, we have ob-
tained structural and biochemical data on both mouse
X1BRCTb and human L3BRCT homodimers, as well as
on the X1BRCTb/L3BRCT heterodimer. Although the
L3BRCT homodimer interface is similar to that
observed for X1BRCTb, several important side-chain
mediated interactions are not conserved between the two
interfaces. These differences are postulated to result in a
weaker homodimerization binding constant for L3BRCT
relative to X1BRCTb. More signiﬁcantly, analysis of the
structure of the X1BRCTb/L3BRCT heterodimer sug-
gested that additional heterodimer stabilization results
from the interaction of residues in the N-terminal linker
region immediately preceding the X1BRCTb domain,
with a hydrophobic region on the L3BRCT domain.
Compelling support for the importance of these inter-
actions has been derived from crystallographic and bio-
chemical studies. These results provide fundamental
insights not only regarding the organization of this im-
portant DNA repair complex, but additionally reveal pre-
viously unknown mechanisms by which protein homo-
and heterodimeric interactions among BRCT containing
proteins can be modulated.
MATERIALS AND METHODS
Cloning overexpression and puriﬁcation
The mouse X1BRCTb domain (residues 535–631) and
the human L3BRCT domain (residues 836–921)
genes were synthesized and cloned into a pUC18 vector
by Genscript. The human ligase III-a gene, with an
N-terminal hexahistidine tag followed by a TEV
protease cleavage site, was subcloned into pETDuet-1
Vector. The X1BRCTb gene, followed by a C-terminal
hexahistidine tag was subcloned into a pET21a vector.
For co-expression with L3BRCT, the X1BRCTb con-
struct, lacking any puriﬁcation tag, was subcloned into a
pCOLADuet-1 vector. For crystallization of the
heteroprotein complex, an X1BRCTb Y574R mutant
was also constructed in a pCOLADuet-1 vector.
The same construct was used to build the X1BRCTb
extended, however, the amino acid sequence
QEPPDLPV, corresponding to the human XRCC1, was
added to the N-terminus of the protein using PCR. For
analytical gel ﬁltration, an X1BRCTb L596R mutant was
constructed. For SAXS analysis, a double mutant
(Y574R/L596R) X1BRCTb was utilized.
Plasmids were transformed into BL21-DE3-RIL cells
and grown in auto-induction media or on LB media sup-
plemented with the appropriate antibiotics. In either case,
at an OD600 of 0.5–1.0, the cultures were cooled to 20C
and allowed to auto-induce, or were induced with 1mM
IPTG, for a total of 18 additional hours. The cells were
harvested by centrifugation (5000g for 10min), resus-
pended in 20mM imidazole, 20mM Tris, 500mM NaCl
(pH 7.5) and lysed by sonication. A cleared lysate was
prepared by centrifugation. Proteins were puriﬁed by
immobilized metal afﬁnity chromatography. A step
gradient of 20, 75 and 400mM imidazole (with 20mM
Tris pH 7.5 and 500mM NaCl) was employed. The
protein eluted in the 400mM aliquot. For TEV protease
digestion, proteins were dialyzed into phosphate-buffered
saline (PBS) and allowed to digest overnight at 4C.
Proteins were further puriﬁed on a Superdex 26/60
S75 (Amersham) gel ﬁltration column. For analytical
gel-ﬁltration, 80ml of protein was loaded onto a
Superdex S75 GL column that was pre-equilibrated with
20mM Tris–HCl (pH 7.8) and either 150mM NaCl or
1M NaCl. A ﬂow rate of 0.5ml/min was used.
Heteroprotein complexes were co-expressed and
co-puriﬁed as above and in all cases produced using
his-tagged L3BRCT co-expressed with X1BRCTb
lacking any tags. Selenomethionine labeled L3BRCT
was produced and puriﬁed as above with the exception
that B834 methionine auxotrophic cells and minimal
media supplemented with 80mg/ml of selenomethionine
was used.
SAXS data acquisition and processing
SAXS data were collected at room temperature on the
X9 beam line at the National Synchrotron Light Source
(Brookhaven National Laboratory). The wavelength of
the beam was 0.92A ˚ and the sample to detector distance
was two meters. The heterodimeric double mutant
(X1BRCTb (Y574R and L596R /wt-L3BRCT)
(2.0–8.0mg/ml) collected from a gel ﬁltration column
were concentrated and dialyzed into a 20mM Na
Phosphate, 1.0mM TCEP and 140mM NaCl pH 7.5
buffer for SAXS analysis; SAXS data was collected on
three dilutions of protein (Supplementary Table S4).
Scattering data were circularly averaged and scaled to
obtain a relative scattering intensity (I) as a function of
momentum transfer vector, q (q=[4sin/l), after subtrac-
tion of buffer scattering contributions.
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All scattering data were analyzed using the Primus
software package (16); the GNOM45 software package
(17) was used for all P(r) and I0 analyzes. The radius of
gyration, Rg and forward scattering, I0, were calculated
from the second moment and the start of P(r), respect-
ively. Rg is the root mean square of all elemental volumes
from the center-of-mass of the particle, weighted by their
scattering densities and I0 is directly proportional to the
molar particle concentration multiplied by the square of
the scattering particle molecular weight for particles with
the same mean scattering density. Guinier plots were
linear over a q-range of 0.017–0.071A ˚ .
Three-dimensional shape of the heterodimer was con-
structed from the SAXS data using the GASBOR22IQW
program (q-range input for analysis was from 0.017 to
0.3A ˚ ) (18), by calculating the distribution of linearly con-
nected 1.9A ˚ spheres that best ﬁt the scattering data. Each
calculation was repeated at least ﬁve times with different
random starting points for the Monte Carlo optimization
algorithm; no predeﬁned shape or symmetry constraints
were used. From these runs, the predicted structure with
the lowest deviation of the calculated scattering proﬁle
from experimental data was used for interpretation. To
compare the SAXS-based models with the atomic struc-
tures, the SUPCOMB13 (19) program was used.
Circular dichroism temperature melts
Circular dichroism (CD) measurements were carried out
on a Jasco spectrophotometer. Thermal denaturations
were determined by measuring the CD signal at 225nm
(1cm path length) as a function of temperature, using
2.5mM protein (10mM Tris–HCl pH 7.8, 20mM NaCl,
0.5mM TCEP). Data were ﬁt to a two-state model to de-
termine the
appTm values (20,21).
Crystallization and data collection
All crystals were grown using hanging drop vapor diffu-
sion, mixing 2ml of the precipitant solution with 2ml of the
protein solution and equilibrating over 900ml of precipi-
tant solution. The L3BRCT domain (12mg/ml dialyzed
into 10mM Tris, 50mM NaCl) was crystallized using
25–35% polyethylene glycol 3350, 0.1M Bis–Tris, pH
6.5, 0.25M ammonium acetate as a precipitant and
frozen in 35% (w/v) polyethylene glycol 3350 for
cryoprotection. Puriﬁed X1BRCTb (12mg/ml dialyzed
into 10mM Tris, 50mM NaCl) was crystallized using
0.5–0.7M Na Formate, pH 7.2–7.5, 0.2M Na HEPES as
a precipitant and frozen in 20% (w/v) ethylene glycol for
cryoprotection. The X1BRCTb(Y39R)/L3BRCT complex
(21mg/ml dialyzed into 10mM Tris, 50mM NaCl and
1mM TCEP) was crystallized using 30% PEG 4000, pH
8.5, 0.1M Tris and 0.2M MgCl2 as a precipitant and cryo-
protectant. Crystals of the X1BRCTb-extended/L3BRCT
(21mg/ml dialyzed into 10mM Tris, 40mM NaCl and
1mM TCEP) were formed using 30% PEG 4000, pH
8.5, 0.1M Tris and 0.2M Na Acetate as a precipitant
and cryoprotectant. X1BRCTb and L3BRCT data were
collected at the SERCAT beamline at the Advanced
Photon Source, Argonne National Laboratory at 100K
using a Mar345 CCD detector. The diffraction data
were scaled and indexed using XDS (22).
X1BRCTb(Y39R)/L3BRCT and X1BRCTb-extended/
L3BRCT data were collected at 100K on a Rigaku
007HF micromax X-ray generator with a Saturn92 CCD
detector. The diffraction data were scaled and indexed
using XDS (22) and HKL2000 (23), respectively.
Structure determination methods, model building
and reﬁnement
The crystal structure of human X1BRCTb (PDB code
1CDZ) was used to solve the structure of the mouse
X1BRCTb to a resolution of 1.9 A ˚ using the PHASER
program (24). No Ramachandran outliers are present in
the model and 99.5% are in the favored Ramachandran
space.
The crystal structure of the mouse X1BRCTb was used
to solve the structure of the human L3BRCT using the
PHASER program (24). The solution was conﬁrmed using
the anomalous signals from the two selenium sites in the
asymmetric unit. The L3BRCT structure was solved to a
resolution of 1.65 A ˚ . No Ramachandran outliers are
present in the model and 98.1% are in the favored
Ramachandran space.
The X1BRCTb(Y574R)/L3BRCT complex was solved
to a resolution of 2.3 A ˚ using the respective monomers
from the X1BRCT band L3BRCT structures utilizing
the PHASER program (24). One Ramachandran outlier
is present in the model and 97.9% are in the favored
Ramachandran space.
The X1BRCTb(Y574R)-extended/L3BRCT complex
was solved to a resolution of 2.26 A ˚ as above. No
Ramachandran outliers are present in the model and
98.3% are in the favored Ramachandran space.
Manual model building was carried out in COOT and
reﬁned using REFMAC5 and PHENIX (25,26). PDB
coordinates and structure factors have been deposited
in the RCSB Protein Data Bank under the accession
codes 3PC6, 3PC7, 3PC8, 3QVG for X1BRCTb,
L3BRCT, X1BRCTb/L3BRCT complex and the
X1BRCTb(Y574R)-extended/L3BRCT complex, respect-
ively. Data collection, reﬁnement and stereochemistry
statistics are summarized in Table 1.
RESULTS
Crystal structure of homodimeric mouse X1BRCTb
Crystals of X1BRCTb were obtained from solutions con-
taining both the X1BRCTb and the L3BRCT constructs,
demonstrating the competitive stability of the X1BRCTb
homodimer and its favorable crystallization. The X-ray
crystal structure of mouse X1BRCTb was solved by mo-
lecular replacement, using the 3.2 A ˚ resolution structure of
human X1BRCT (PDB code 1CDZ) (11), to a resolution
of 1.9 A ˚ . The mouse X1BRCTb adopts the globular
a/b-fold that is characteristic of BRCT domains and has
a 0.5 A ˚ RMSD of Ca atoms with the human X1BRCTb
structure (Figure 1). The two monomers in the asymmetric
unit correspond to the same homodimer interface
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Figure 1. Structure of the X1BRCTb homodimer. (A) Ribbon diagram of the X1BRCTb homodimer. The monomers are colored in cyan and blue.
(B) Close-up view of the hydrogen bonding network between X1BRCTb monomers. (C) Close-up view of the homodimer interface illustrating the
hydrophobic contacts. Amino acid side-chains that are found to be part of the interface are represented as stick models. Labels are shown only for
hydrophobic residues.
Table 1. Data collection and reﬁnement statistics
L3BRCT X1BRCTb X2BRCTb(Y39R)/
L3BRCT
extended-X2BRCTb(Y39R)/
L3BRCT
Resolution Range (A ˚ ) 50.0–1.65 50.0–1.90 35.0–2.31 35.0–2.26
Unique reﬂections 19139 20146 17611 18358
Redundancy 9.3 (8.8) 5.1 (3.5) 6.6 (5.4) 6.3 (3.3)
Mean I/s(I)
a 26.9 (4.8) 23.6 (4.8) 26.1 (6.4) 20.6 (4.9)
Rmerged (%)
a 6.9 (42.2) 6.2 (23.1) 5.3 (33.6) 7.1 (26.1)
Completeness (%)
a 98.9 (100) 97.4 (82.8) 96.0 (83.2) 97.5 (80.4)
Unit cell
Dimensions (A ˚ ) a/b=70.1 a=44.2 a=66.3 a=38.1
c=62.3 b=56.9 b=163.5 b=61.5
c=100.4 c=36.7 c=163.7
Angles ()
Space group P43212 P212121 P21212 P212121
Non-hydrogen atoms in reﬁnement
Protein 1313 1761 2936 3060
Water 176 183 208 297
Rcryst/Rfree (%)
b 14.1/19.7 18.0/22.7 19.7/24.7 19.9/27.0
R.m.s.d. from ideal
Bond lengths (A ˚ ) 0.008 0.006 0.004 0.003
Bond angles () 1.1 0.863 0.721 0.6
B-factors (A ˚ 2)
Chain A=26.9,
Chain B=28.8
Chain A=27.1,
Chain B=26.1
Chain AC=33.2,
Chain BD=38.4
Chain AB=28.2,
Chain CD=31.2
Water 41.3 34.5 37.7 33.6
aNumber in parentheses represent values in the highest resolution shell.
bRfree is the Rfactor based on 5% of data excluded from reﬁnement.
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though the current X1BRCTb structure crystallized with
a different unit cell and space group, a similar crystallo-
graphic symmetry mate is found interacting through the
b4 and C-terminal region of each protein. Based on our
gel-ﬁltration data (below) of an L596R mutation at this
interface, we demonstrate that this surface is important for
tetramer formation.
Although consistent with the lower resolution structure,
the higher resolution structure presented here allows for
better modeling of the main- and side-chain atoms. A total
of 19 hydrogen bonds are formed across the protein inter-
face (Supplementary Table S1). The hydrogen-bonding
pattern is not exactly symmetric across the homodimer.
The side-chain of Asp539 is in an alternate rotamer in
chain A whereas the rotamer in chain B allows formation
of a hydrogen bond with the Z hydrogen of Arg562.
Additionally, electron density for the side-chain of
Glu570 is not observed for chain B (Supplementary
Table S1). The remainder of the interface consists of a
network of non-polar amino acids in the core of the inter-
face (Figure 1); all together polar and non-polar amino
acids contribute a total of 1205 A ˚ 2 of buried surface area
to the interprotein interface.
Crystal structure of the homodimeric human L3BRCT
As with X1BRCTb, crystals of L3BRCT were obtained
from solutions containing both the X1BRCTb and the
L3BRCT constructs. The X-ray crystal structure of the
human L3BRCT was solved by molecular replacement
to a resolution of 1.65 A ˚ , using a monomer from the
mouse X1BRCTb structure (Figure 2). Two molecules
are found in the asymmetric unit. Analysis of
symmetry-related molecules reveals that two distinct crys-
tallographic homodimers are formed with substantial
interface contacts involving residues predicted to be at
the interface by Dulic et al. (13) and consistent with the
X1BRCTb homodimer interface (Figure 2). One of the
L3BRCT homodimers adopts an orientation that is
similar to that of the X1BRCTb homodimer (RMSD
value of 1.8 A ˚ for Ca atoms). The second L3BRCT
homodimer is related to the ﬁrst by a 13 difference in
orientation of monomers across the homodimer interface,
resulting in a more closed structure and altered protein
interface (Figure 2).
In the homodimer that is structurally similar to
X1BRCTb, a total of 16 hydrogen bonds are formed
across the L3BRCT interface (Supplementary Table S2).
Arg870, a structural analog of Arg562 in X1BRCTb, has
seven potential partners within hydrogen bonding distance
with the second monomer (Figure 2), interacting with the
same conserved network of amino acids found in
X1BRCTb. The remainder of the interface consists of a
network of non-polar amino acids contributing a total of
1365 A ˚ 2 of buried surface area (Figure 2).
In the second homodimer (Figure 2 and Supplementary
Table S2), the hydrogen-bonding pattern of Arg870 is the
same, however a hydrogen bond between Tyr871 and
Leu847 is lost. The loss of this hydrogen bond is
compensated by the formation of two additional
hydrogen bonds pairing the side-chain of Arg869 with
the main-chain of Leu879 and the side-chain of Asp878
(Figure 2). An additional hydrogen bond is also likely to
be formed across the crystallographic 2-fold axis between
the side-chain atoms of Gln881. The altered conformation
of the two monomers also alters the non-polar surface of
the interface. An additional hydrophobic region surround-
ing Gln881, contributes a total of 50 A ˚ 2 of buried
surface area to the interface. The polar and non-polar
amino acids of closed L3BRCT homodimer contribute a
total of 1304 A ˚ 2 of buried surface area in the interprotein
interface, which is similar to the more open homodimer
(Figure 2).
Crystal structure of the heterodimeric X1BRCTb/
L3BRCT complex
As mentioned above, X1BRCTb and L3BRCT homo-
dimer crystals were obtained in some of the studies
designed to crystallize the X1BRCTb/L3BRCT hetero-
dimer, demonstrating the competitive stability of the
hetero- and homodimers. An alternate crystal form of
the X1BRCTb homodimer revealed an additional
symmetry-related molecule in whichTyr574 formed signiﬁ-
cant interactions with the X1BRCTb homodimer
(Supplementary Figure S1). We hypothesized that a
non-conservative substitution for Tyr574 would interfere
with the observed interactions and facilitate alternate crys-
tallization conditions that could include heterodimer
structures. Consistent with this hypothesis, mutation of
this residue to arginine resulted in crystallization of
the desired X1BRCTb/L3BRCT heterodimer complex.
The mutated Y574R residue is not involved in any of
the crystallographic interfaces, although it does mediate
lattice contacts. In support of the mutational strategy
that we have adopted, the corresponding residue in the
human XRCC1, Tyr576, exhibits an infrequent Y576S
polymorphism, which appears not to inﬂuence either the
stability or the function of the protein (15).
Consistent with the biochemically observed tetrameric
quaternary structure, the four molecules found in the crys-
tallographic asymmetric unit assemble into a homodimer
of heterodimers (Figure 3). The interface of the two
heterodimers involves only the two X1BRCTb domains.
The two heterodimers adopt similar conformations with a
Ca MSD of 0.7 A ˚ ; in the discussion below, the homodimer
with the highest structural homology (0.2 A ˚ RMSD for
Ca atoms of heterodimer chains A/C) to the X1BRCTb is
used. The X1BRCTb and L3BRCT interfaces involved in
heterodimer formation are essentially identical with the
interfaces used for homodimer formation. Similarly, the
X1BRCTb homodimer interface is identical to the crystal-
lographic protein interface that is observed in both the
current and the previously determined X1BRCTb
homodimers (11).
Numerous polar and non-polar interactions are present
at the heterodimer interface with a total of 1210 A ˚ 2 of
buried surface area forming the interprotein interface,
while there are a total of 18 potential partners within
hydrogen bonding distance with the second monomer.
The residues involved in heterodimer hydrogen bonding
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homodimer (Figure 3 and Supplementary Table S3).
Arg558 and Arg562 from X1BRCTb each form four
hydrogen bonds with L3BRCT. Arg869 from L3BRCT
forms a hydrogen bond with the side-chain of Glu570
from X1BRCTb. Arg870 from L3BRCT forms four
hydrogen bonds with X1BRCTb. The remaining inter-
protein hydrogen bonds are formed through the inter-
action of the hydroxyl of Tyr871 from L3BRCT with
the main-chain carbonyl of Pro535 and the main-chain
nitrogen of Leu537. We also note that although the
heterodimer corresponds to the a complex of the mouse
X1BRCTb with the human L3BRCT, none of the
sequence differences involve interface residues.
The X1BRCTb homodimer interface in the tetramer
corresponds to a 2-fold non-crystallographic rotation
axis. There are few interprotein hydrogen bonding inter-
actions in this homodimer interface, which is composed
mainly of non-polar residues (Figure 3). All together,
polar and non-polar amino acids contribute a total of
1020 A ˚ 2 of buried surface area to the interprotein inter-
face. Four hydrogen bonds are formed across the interface
(Figure 3). A large number of non-polar amino acids con-
tribute to this interface with a densely packed core con-
sisting of Trp588, Phe604, Leu602 and Leu596 from one
monomer forming Van der Waals interactions with
Pro621 and Leu624 from the other monomer. As this
interface is found at a 2-fold non-crystallographic axis,
the interactions are similar in both half sites. Interestingly,
separating both half sites is a water-ﬁlled pocket con-
taining the His622 side-chains and with Val624 and
Val627 from both monomers forming a water-excluding
base so that only one end is solvent accessible. Based on
the chromatographic data obtained for the L596R
interface-disrupting mutation (below), we demonstrate
this is the biochemically relevant salt-dependent tetramer
interface.
Gel-ﬁltration chromatography of the XRCC1 and
ligase III-a BRCT domains
Previously reported biochemical studies have demon-
strated that the X1BRCTb/L3BRCT complex can form
tetramers that are favored under lower salt conditions
(12). The crystallographic asymmetric unit of the
X1BRCTb/L3BRCT structure contains a homodimer of
heterodimers. The homodimer interface is formed through
the X1BRCTb domains interacting in an identical manner
to the homotetramer interface observed in the X1BRCTb
homodimer structures (11). However, since this interface is
primarily hydrophobic, it was not clear that the associ-
ation present in the crystal would be favored under
AB
CD
Figure 2. Structure of homodimeric L3BRCT. Two conformationally distinct homodimers were identiﬁed in the crystal structure and are shown in
(A) and (B). The two structures differ by 13 in the relative orientation of the L3BRCT monomers. (C) Close-up view of the interface amino acids
and hydrogen bonding network between the L3BRCTmonomers from the homodimer in (A). (D) Close-up view of the interface amino acids and
hydrogen-bonding network between the L3BRCTmonomers from the homodimer in (B). Hydrogen bonds between monomers are represented as
black dashed lines and residues involved in hydrogen bonds are labeled.
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viously observed.
To determine if the tetramer interfaces are the same in
the X1BRCTb homodimer and the X1BRCTb/L3BRCT
heterodimer, gel-ﬁltration experiments of these proteins
were carried out in the presence of lower, more physiolo-
gically relevant (150mM NaCl) and higher (1M NaCl)
salt conditions (Figure 4). In the presence of 150mM
NaCl, the complex elutes at an apparent molecular mass
of 45.0kDa, whereas under high salt conditions, the
complex elutes at an apparent molecular mass of
30.3kDa; the expected molecular mass is 21.3kDa.
These results are consistent with the behavior previously
reported for isolated X1BRCTb (12), suggesting that
tetramer formation is mediated through the same
X1BRCTb interface. To further evaluate the relevance
of this interface, an L596R mutation based on the
crystal structure was introduced to disrupt the interface.
This mutant elutes from the gel-ﬁltration column in
150mM NaCl at an apparent molecular weight of
26.2kDa consistent with disruption of the tetramer inter-
face (Figure 4).
A
BC
D
Figure 3. Structure of X1BRCTb/L3BRCT tetramer. (A) Overall structure of the tetrameric X1BRCTb/L3BRCT complex (L3BRCT monomers
are represented as red and magenta ribbon models; X1BRCTb monomers are represented as blue and cyan ribbon models). The 2-fold
non-crystallographic axis in the z-plane of the page is represented as a black circle. (B) Close-up view of the X1BRCTb/L3BRCT heterodimer
interface (amino acids found at the interface are shown in stick representation. (C) X1BRCTb/L3BRCT heterodimer from view (B) rotated 180
about the y-axis. The hydrophobic cleft on L3BRCT is shown in a grey surface representation. (D) Close-up view of the homodimer interface from
the X1BRCTb/L3BRCT heterodimer (amino acids found at the interface are shown in stick representation, L596 is shown as a gray surface and
water molecules are shown as red spheres).
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The interaction of X1BRCTb with L3BRCT was
investigated using small-angle X-ray scattering (SAXS).
Both the wild-type proteins and the heterodimer were sig-
niﬁcantly polydisperse as judged by the SAXS intensity
data. However, the observed polydispersity was reduced
in samples of a double mutant heterodimeric complex
X1BRCTb (Y574R and L596R/wt-L3BRCT). Io molecu-
lar weight analysis of the SAXS data on a 2.0mg/ml
double mutant sample, based upon the scattering of a
lysozyme standard, produces the expected molecular
weight of 20.7kDa, consistent with the gel ﬁltration ex-
periments of the single L596R single mutant and the mo-
lecular weight based on amino acid composition
(21.3kDa) (Supplementary Table S4). The experimental
radius of gyration (19.2 A ˚ ) and the intensity scattering
proﬁle of the double-mutant heterodimer also match the
X-ray crystal structure calculated radius of gyration (19.1
A ˚ ) and intensity data (Figure 5 and Supplementary Table
S4). The SAXS intensity data was used to construct an
ab initio model of the mutant heterodimer in solution.
The SAXS-based model of this complex has an overall
shape consistent with the X-ray crystal structure,
indicating that the relative orientation of the monomers
seen in the crystal structures is maintained in solution
(Figure 5). Additionally, superposition of the SAXS
model with the crystal structure model produces an
RMSD of 0.92 A ˚ .
Partitioning of L3BRCT homodimers
Many of the hydrogen bonds and hydrophobic inter-
actions contributing to the observed interface are conser-
ved in both proteins. However, additional non-conserved
hydrogen bonds found in the X1BRCTb homodimer have
interesting implications for heterodimer/homodimer
partitioning. Arg558 in X1BRCTb can form a total of
six interprotein hydrogen bonds with the side-chains of
Glu570 and Asn568, and with the main-chain carbonyl
of Gly569. In L3BRCT, the residue corresponding to
Arg558 is a serine (Ser866), but the residues corresponding
to Glu570 (Asp878), Asn568 (Asp876) and Gly569
(Gly877) are conserved (Figure 6). Indeed, in both
L3BRCT homodimers, the analogous hydrogen bonds
are missing whereas they are present in the heterodimer.
Additionally, Arg869 in the L3BRCT homodimer is also
found in an electrostatically unfavorable position relative
to Arg869 in the opposite monomer (Figure 6). In the
heterodimer, this unfavorable interaction is not present
as Arg869 is replaced with an isoleucine in X1BRCTb,
so that Arg869 instead hydrogen bonds with the
side-chain of Glu570 (Figure 6). In the structure of the
ligase homodimer that is characterized by a more closed
orientation, these arginine residues adopt an alternate
rotamer to alleviate this unfavorable interaction. For the
interactions summarized above, the heterodimer allows
for the formation of additional hydrogen bonds while
alleviating unfavorable electrostatic interactions found in
the ligase homodimer. These interactions provide one
basis for homodimer/heterodimer discrimination.
Partitioning of X1BRCTb homodimers
Unlike L3BRCT, the X1BRCTb homodimer essentially
has the same hydrogen-bonding network as the hetero-
dimer, suggesting homodimer and heterodimer complexes
have similar binding constants. We postulated that
there must exist mechanisms favoring formation of the
heterodimer over the homodimer. Based upon positioning
of the N-terminus of the X1BRCTb in the heterodimer, we
identiﬁed a cluster of surface residues in L3BRCT that
appeared to provide a potential binding site for additional
N-terminal amino acids that were not present in our
crystallization constructs. These N-terminal residues are
not conserved in L3BRCT, nor is the analogous cluster
of surface residues conserved in X1BRCTb, suggesting a
possible role of this groove in partitioning the X1BRCTb
homodimer to favor formation of the heterodimer.
To test this hypothesis, a longer chimeric mouse
X1BRCTb was constructed that consisted of an additional
eight residues from the human XRCC1 on the N-terminus
[X1BRCTb(Y574R)-extended]. The heterodimeric struc-
ture of X1BRCTb(Y574R)-extended and L3BRCT was
solved to a resolution of 2.26 A ˚ . As anticipated, based
upon analysis of the original crystal structure, the
N-terminus of X1BRCTb(Y574R)-extended formed
numerous speciﬁc contacts with the ligase (Figure 7).
These added N-terminal residues form an additional
500A ˚ 2 of buried surface area for total of 1749 A ˚ 2 for
the C/D chains of this protein complex. Interestingly, in
the A/B chains of this complex, the N-terminus of the
ligase is additionally ordered, forming an even larger
buried surface area, for a total of 1923 A ˚ 2. Both polar
and non-polar contacts are made with these extra
residues, with Val534 and Pro535A being placed into
what would be a solvent exposed hydrophobic pocket in
the ligase homodimer. A total of four hydrogen bonds are
formed with the additional residues in the extended
Figure 4. Gel-ﬁltration of X1BRCTb complexed with L3BRCT.
X1BRCTb/L3BRCT in 150mM NaCl (black dashed line) and 1M
NaCl (gray solid line), and X1BRCTb Leu596Arg/L3BRCT in
150mM NaCl (gray dashed line). The straight line (black) is a ﬁt of
the gel ﬁltration standards (black squares) used to estimate the molecu-
lar mass of the complexes.
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Figure 6. Conservation of X1BRCTb/L3BRCT protein interface residues. (A) Amino acid composition of the X1BRCTb and L3BRCT homodimer
interface. Amino acids composing the protein interfaces are highlighted in red and those involved in hydrogen-bonding interactions are underlined.
(B) X1BRCTb hydrogen-bonding network superimposed with the conserved residues from L3BRCT. X1BRCTb monomers are colored in blue
tones; side-chains involved in forming the interface and homodimer hydrogen bonds are colored the same, numbered and shown as stick rep-
resentations. Side-chains from the L3BRCT homodimer are also shown as stick representations that are colored orange and magenta. (C) L3BRCT
hydrogen bonding network superimposed with the conserved residues from X1BRCTb [colored as in (B)]. Residues circled in (B) and (C) are circled
in (A).
Figure 5. Small-angle X-ray scattering of double mutant heterodimer. (A) SAXS intensity data of X1BRCTb(Y574R,L596R)/L3BRCT heterodimer.
Black line is the raw scattering data with associated errors and the red line is the ﬁt to the X-ray crystal structure of the X1BRCTb/L3BRCT dimer
from the tetrameric crystal structure. Insets are the Guinier ﬁt and the pair-wise distribution function. (B) Ab initio SAXS envelope model
superimposed with the X-ray crystal structure of the X1BRCTb/L3BRCT dimer from the tetrameric crystal structure. X1BRCTb is shown in a
cyan ribbon representation and L3BRCT is shown in a magenta ribbon representation.
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X1BRCTb(Y574R)-extended and Lys915 of the ligase
(Figure 7). Two additional amino acids were included
in the construct prior to Glu528; however, they were
disordered and do not interact with the ligase. The
above-mentioned interactions are unlikely to be formed
in the X1BRCTb homodimer. The hydrophobic pocket,
into which Val534 and Pro535 are placed, is occluded by
the side-chain of Asn614 and Gln617 in the X1BRCTb
homodimer. Taken together these factors suggest a struc-
tural mechanism for a partitioning between homo- and
heterodimer complexes.
Thermal melting (Tm) point determinations were per-
formed to further evaluate the stabilizing role of the
N-terminus in the heterodimer. The presence of the add-
itional N-terminal residues in the X1BRCTb(Y574R)-
extended construct elevated the melting temperature by
7.7 to 63.9C, compared with the Tm=56.2C obtained
for the heterodimer lacking the extension (Figure 7).This
increase in Tm is directly related to the additional free
energy of binding of the extended heteroprotein
complex. The Tm of the extended homodimer is 60.3C,
supporting the above-mentioned conclusion that the
analogous interactions are not present. There is also a
signiﬁcant decrease in cooperativity of the melting transi-
tion, suggesting that these residues in the homodimer lead
to destabilization, rather than the stabilization observed
in the heterodimer. Additionally, the non-extended
X1BRCTb homodimer has a Tm of 54.3C, only 1.9C
less stable than the shorter heterodimer. This small differ-
ence in Tm clearly indicates the shorter heteroprotein
complex is only slightly more stable than the X1BRCTb
homodimer, and therefore suggests small differences in
the binding constants of these complexes, while providing
an explanation for the observed crystallization of
homodimers from a solution of heterodimer.
DISCUSSION
The continuing identiﬁcation of binding partners for
XRCC1 reﬂects an evolving understanding of the
multiple roles played by this protein in DNA repair
processes (1,5,27–29). Coordination of the individual
steps involved in DNA repair is of critical importance
due to the lability of many of the intermediates
involved. XRCC1 is postulated to play a central role in
spatial organization of DNA repair factors, facilitating
efﬁcient transfer of repair intermediates. Among the
many XRCC1 interactions that have been identiﬁed,
only one, the complex formed with ligase III-a, is con-
sidered to be constitutive (1,8,29). This interaction has
been shown to stabilize the ligase, increasing the catalytic
efﬁciency of the ligation reaction (6), playing a role in both
nucleotide- and base excision repair. The present study
contains the ﬁrst structural characterization of the
X1BRCTb/L3BRCT complex that forms the basis for
this constitutive interaction, and further demonstrates
that a tetramer consisting of two X1BRCTb/L3BRCT
heterodimers forms involving direct contact of the two
X1BRCTb domains.
The X1BRCTb homodimer was the ﬁrst BRCT domain
to be structurally characterized (11).This structure, in
A
B
C
Figure 7. Structure of the X1BRCTb(Y574R)-extended/L3BRCT complex. (A) Overall structure of the tetrameric X1BRCTb(Y574R)-extended/
L3BRCT complex (L3BRCT monomers are represented as red and magenta ribbon models; X1BRCTb(Y574R)-extended monomers are represented
as blue and cyan ribbon models). (B) Close-up view of the X1BRCTb-extended/L3BRCT heterodimer interface (amino acids found at the interface
are shown in stick representation and amino acids composing the L3BRCT peptide-binding site are shown as a pale green surface; non-interacting
surfaces of the ligase are colored in magenta). (C) Circular dichroism temperature melts of X1BRCTb (green), X1BRCTb(Y574) extended (blue),
X1BRCTb/L3BRCT (black), X1BRCTb(Y574R)-extended/L3BRCT (red). Inset is a schematic representing the constructs used for the temperature
melts (X1, X1BRCTb; L3, L3BRCT).
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the proposal that BRCT-mediated protein complexes
could be based on analogous heterodimers. However, ex-
perimental evidence for such structures has proven so
elusive that alternative proposals have been advanced,
such as the suggestion that the XRCC1/ligase III-a
complex involves the association of two BRCT-domain
homodimers (12) and the identiﬁcation of differing
binding epitopes of XRCC1 (7,12,30). An additional
problem inherent in the heterodimer model results from
the lack of an obvious basis for the selection of the
heterodimer over the homodimer.
The structures presented here resolve these issues,
demonstrating that the X1BRCTb and L3BRCT
homodimers as well as the X1BRCTb/L3BRCT
heterodimer all utilize a common interface. An alternative
ligase-binding element identiﬁed by Taylor et al. (7)
(mouse XRCC1 residues 571–590), which is related to
the C1/C3 loop binding epitope discussed by Huyton
et al. (30), has 50% amino acid similarity to the
heterodimer interface identiﬁed here that includes alpha
helix 1 and surrounding residues (mouse XRCC1
residues 552–571). This provides a possible explanation
for the earlier observation of binding afﬁnity of this con-
struct to L3BRCT. The competitive dimerization dilemma
inherent in the earlier proposals has also been resolved
with the demonstration that residues in the linker imme-
diately preceding the X1BRCTb domain interact with
L3BRCT, signiﬁcantly expanding the buried surface area
and leading to enhanced stability of the heterodimer, as
demonstrated by thermal melting curves. Alternatively,
analysis of the homodimer structures indicates that no cor-
responding stabilization would result from analogous
interactions in the homodimers. Additionally, based both
on the structure reported here as well as the previous NMR
study (15), the L3BRCT homodimer complex is less stable
than the X1BRCTb homodimer. It is likely that the
homodimers serve additional roles, e.g. providing a stable
intermediate species in the absence of the heterodimer
binding partner that could function to reduce non-speciﬁc
interactions and/or protein degradation.
BRCT domains are a common protein interaction
module serving fundamental roles in cell signaling and
DNA repair pathways. The canonical tandem BRCT
domain forms an asymmetric homodimer that creates a
phosphopeptide binding site (31). The most common
BRCT-mediated protein binding modality identiﬁed to
date involves BRCT repeats with protein domains of dif-
ferent structure. Examples include p53-53BP1 (32,33)
and XRCC1/ligase-IV (34). The symmetric heterodimer
structure presented here represents an alternative
protein-protein dimerization modality. However, all of
these BRCT-mediated complexes demonstrate a common
strategy of utilizing additional linker residues to achieve
greater afﬁnity and speciﬁcity.
The interaction of XRCC1 with DNA ligase III-a and
the defective DNA repair phenotype associated with its
disruption was identiﬁed by Caldecott and colleagues (6).
Subsequent work demonstrated that the interaction of
these proteins was between the C-terminal BRCT
domains of each protein, in which the ligase is distally
located from the core catalytic domain (7). The question
has therefore remained as to why the interaction of
XRCC1 with DNA ligase III-a would have an effect on
repair efﬁciency. The structure of the heteroprotein
complex provides some insight regarding its function.
XRCC1 interacts with both APE1 (2) and DNA polymer-
ase b (35), the enzymes involved in the earlier steps of base
excision repair. The interaction of XRCC1 with DNA
ligase III-a serves as a means to increase the effective
concentration of the ligase at these reaction centers.
Moreover, the peptide binding site on the surface of the
ligase may be a structural feature involved in positioning
the N-terminal domains of XRCC1, and in-turn APE1 and
DNA polymerase b, so as to be in an optimal position for
hand-off of the DNA repair intermediates to the ligase.
The functional role, if any, of a dimeric repair complex
mediated by the observed tetrameric heterodimer inter-
actions remains unknown, however experiments are
currently in progress to determine if a defective DNA
repair phenotype is associated with the tetramer-
disrupting L596R XRCC1 mutation. These experiments
may provide insights into the possible role of a dimeric
XRCC1 complex in efﬁcient DNA repair.
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